Hiprabovis IBR Marker Live


live gene-deleted vaccine for intramuscular use for active immunisation of cattle against infectious bovine rhinotracheitis

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 06/07/2017

Authorisation details

Product details
Hiprabovis IBR Marker Live
Agency product number
Active substance
live gE- tk- double-gene-deleted bovine herpes virus type 1, strain CEDDEL: 106.3–107.3 CCID50
International non-proprietary name (INN) or common name
live gene-deleted vaccine for intramuscular use for active immunisation of cattle against infectious bovine rhinotracheitis
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Laboratorios Hipra S.A
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Avda. La Selva 135
17170 Amer (Girona)

Product information

22/06/2017 Hiprabovis IBR Marker Live - EMEA/V/C/000158 - IG/0793

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

For the active immunisation of cattle from three months of age against bovine herpes virus type 1 (BoHV-1) to reduce the clinical signs of infectious bovine rhinotracheitis (IBR) and field virus excretion.

Onset of immunity: 21 days after completion of the basic vaccination scheme.

Duration of immunity: 6 months after completion of the basic vaccination scheme

Assessment history


How useful was this page?

Add your rating
1 rating
1 rating